- Home
- DYN vs CDTX Comparison
DYN vs CDTX Comparison
Compare DYN & CDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DYN
- CDTX
- Stock Information
- Founded
- DYN 1984
- CDTX 2012
- Country
- DYN United States
- CDTX United States
- Employees
- DYN N/A
- CDTX N/A
- Industry
- DYN Medicinal Chemicals and Botanical Products
- CDTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DYN Health Care
- CDTX Health Care
- Exchange
- DYN Nasdaq
- CDTX Nasdaq
- Market Cap
- DYN 1.9B
- CDTX 1.6B
- IPO Year
- DYN 2020
- CDTX 2015
- Fundamental
- Price
- DYN $14.51
- CDTX $98.51
- Analyst Decision
- DYN Strong Buy
- CDTX Strong Buy
- Analyst Count
- DYN 14
- CDTX 11
- Target Price
- DYN $34.93
- CDTX $91.60
- AVG Volume (30 Days)
- DYN 2.5M
- CDTX 1.2M
- Earning Date
- DYN 11-11-2025
- CDTX 11-06-2025
- Dividend Yield
- DYN N/A
- CDTX N/A
- EPS Growth
- DYN N/A
- CDTX N/A
- EPS
- DYN N/A
- CDTX N/A
- Revenue
- DYN N/A
- CDTX N/A
- Revenue This Year
- DYN N/A
- CDTX N/A
- Revenue Next Year
- DYN N/A
- CDTX N/A
- P/E Ratio
- DYN N/A
- CDTX N/A
- Revenue Growth
- DYN N/A
- CDTX N/A
- 52 Week Low
- DYN $6.36
- CDTX $10.14
- 52 Week High
- DYN $35.90
- CDTX $106.63
- Technical
- Relative Strength Index (RSI)
- DYN 59.18
- CDTX 73.40
- Support Level
- DYN $12.43
- CDTX $96.35
- Resistance Level
- DYN $14.27
- CDTX $106.63
- Average True Range (ATR)
- DYN 0.73
- CDTX 6.45
- MACD
- DYN 0.04
- CDTX 1.55
- Stochastic Oscillator
- DYN 85.53
- CDTX 86.26
About DYN Dyne Therapeutics Inc.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
About CDTX Cidara Therapeutics Inc.
Cidara Therapeutics Inc is developing immunotherapeutics designed to help improve the standard of care for patients facing serious diseases. Its clinical-stage asset is CD388, a DFC intended for influenza prophylaxis. The Company's portfolio comprises new approaches aimed at transforming existing treatment and prevention paradigms, including DFCs from its proprietary Cloudbreak platform targeting oncologic, viral and autoimmune diseases.